Literature DB >> 17160018

PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response.

V Ayllón1, R O'connor.   

Abstract

The contribution of the insulin-like growth-factor-I receptor (IGF-IR) to tumour progression is well documented. To identify new mediators of IGF-IR function in cancer, we recently isolated genes differentially expressed in cells overexpressing the IGF-IR. Among these was the serine/threonine kinase PBK/TOPK (PDZ-binding kinase/T-LAK cell-originated protein kinase), previously associated with highly proliferative cells and tissues. Here, we show that PBK is expressed at high levels in tumour cell lines compared with non-transformed cells. IGF-I could induce PBK expression only in transformed cells, whereas epidermal growth factor could induce PBK in non-transformed MCF-10A breast epithelial cells. Suppression of PBK expression using small interfering RNA did not prevent progression through the cell cycle, but caused decreased proliferation over time in culture, and reduced clonogenic growth in soft agarose. PBK knockdown impaired p38 activation after long-term stimulation with different growth factors and reduced DU145 cells motility. Suppressed PBK expression also resulted in an impaired response to DNA damage that was evident by the decreased generation of gamma-H2AX, increased DNA damage and decreased cell survival. Taken together, the data indicate that PBK is necessary for appropriate activation and function of the p38 pathway by growth factors. Thus, enhanced expression of PBK may facilitate tumour growth by mediating p38 activation and by helping cells to overcome DNA damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160018     DOI: 10.1038/sj.onc.1210142

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  65 in total

1.  T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity.

Authors:  Tatyana A Zykova; Feng Zhu; Tatyana I Vakorina; Jishuai Zhang; Lee Ann Higgins; Darya V Urusova; Ann M Bode; Zigang Dong
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

2.  Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human Breast Cancer Cells.

Authors:  Lancelot S McLean; Cheri N Watkins; Petreena Campbell; Dain Zylstra; Leah Rowland; Louisa H Amis; Lia Scott; Crystal E Babb; W Joel Livingston; Agus Darwanto; Willie L Davis; Maheswari Senthil; Lawrence C Sowers; Eileen Brantley
Journal:  Chem Res Toxicol       Date:  2015-04-01       Impact factor: 3.739

3.  Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin.

Authors:  Roger Gilabert-Oriol; Brent W Sutherland; Malathi Anantha; Alessia Pallaoro; Marcel B Bally
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

4.  CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity.

Authors:  Seth Stauffer; Yongji Zeng; Jiuli Zhou; Xingcheng Chen; Yuanhong Chen; Jixin Dong
Journal:  Cell Signal       Date:  2017-08-03       Impact factor: 4.315

5.  Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.

Authors:  Adwitiya Kar; Yu Zhang; Betelehem W Yacob; Jordan Saeed; Kenneth D Tompkins; Stacey M Bagby; Todd M Pitts; Hilary Somerset; Stephen Leong; Margaret E Wierman; Katja Kiseljak-Vassiliades
Journal:  Endocr Relat Cancer       Date:  2019-10       Impact factor: 5.678

6.  Expression of cancer/testis antigens in prostate cancer is associated with disease progression.

Authors:  Takahito Suyama; Takumi Shiraishi; Yu Zeng; Wayne Yu; Nehal Parekh; Robert L Vessella; Jun Luo; Robert H Getzenberg; Prakash Kulkarni
Journal:  Prostate       Date:  2010-12-01       Impact factor: 4.104

7.  ADA-07 Suppresses Solar Ultraviolet-Induced Skin Carcinogenesis by Directly Inhibiting TOPK.

Authors:  Ge Gao; Tianshun Zhang; Qiushi Wang; Kanamata Reddy; Hanyong Chen; Ke Yao; Keke Wang; Eunmiri Roh; Tatyana Zykova; Weiya Ma; Joohyun Ryu; Clara Curiel-Lewandrowski; David Alberts; Sally E Dickinson; Ann M Bode; Ying Xing; Zigang Dong
Journal:  Mol Cancer Ther       Date:  2017-06-27       Impact factor: 6.261

8.  Expression of PBK/TOPK in cervical cancer and cervical intraepithelial neoplasia.

Authors:  Qiong Luo; Bin Lei; Shuguang Liu; Yaowen Chen; Wenjie Sheng; Peixin Lin; Wenxia Li; Haili Zhu; Hong Shen
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

9.  Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.

Authors:  D Herrero-Martín; D Osuna; J L Ordóñez; V Sevillano; A S Martins; C Mackintosh; M Campos; J Madoz-Gúrpide; A P Otero-Motta; G Caballero; A T Amaral; D H Wai; Y Braun; M Eisenacher; K-L Schaefer; C Poremba; E de Alava
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

10.  Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.

Authors:  I Zlobec; F Molinari; M Kovac; M P Bihl; H J Altermatt; J Diebold; H Frick; M Germer; M Horcic; M Montani; G Singer; H Yurtsever; A Zettl; L Terracciano; L Mazzucchelli; P Saletti; M Frattini; K Heinimann; A Lugli
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.